Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Stephen O'Quinn"'
Autor:
Joseph M. Palumbo, Brian F. Thomas, Dejan Budimirovic, Steven Siegel, Flora Tassone, Randi Hagerman, Christopher Faulk, Stephen O’Quinn, Terri Sebree
Publikováno v:
Journal of Neurodevelopmental Disorders, Vol 15, Iss 1, Pp 1-10 (2023)
Abstract Multiple lines of evidence suggest a central role for the endocannabinoid system (ECS) in the neuronal development and cognitive function and in the pathogenesis of fragile X syndrome (FXS). This review describes the ECS, its role in the cen
Externí odkaz:
https://doaj.org/article/3535becc2cfc44cc9aac3af5f1bbeae2
Autor:
Elizabeth Berry-Kravis, Randi Hagerman, Dejan Budimirovic, Craig Erickson, Helen Heussler, Nicole Tartaglia, Jonathan Cohen, Flora Tassone, Thomas Dobbins, Elizabeth Merikle, Terri Sebree, Nancy Tich, Joseph M. Palumbo, Stephen O’Quinn
Publikováno v:
Journal of Neurodevelopmental Disorders, Vol 14, Iss 1, Pp 1-15 (2022)
Abstract Background Fragile X syndrome (FXS) is associated with dysregulated endocannabinoid signaling and may therefore respond to cannabidiol therapy. Design CONNECT-FX was a double-blind, randomized phase 3 trial assessing efficacy and safety of Z
Externí odkaz:
https://doaj.org/article/9b2b2328cf084b42bc90fb9b752f13e7
Autor:
Nancy Tich, Elizabeth Merikle, Thomas Dobbins, Stephen O'Quinn, Terri B. Sebree, Joseph Palumbo
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 60:S258
Objectives: ZYN002 is a pharmaceutically manufactured transdermal cannabidiol gel in development for the treatment of behavioral symptoms in Fragile X syndrome (FXS). RECONNECT is a pivotal, randomized, double-blind, Phase 3 trial to assess the effic
Autor:
Joseph Palumbo, Elizabeth Merikle, Thomas Dobbins, Stephen O'Quinn, Nancy Tich, Vanessa Perez Patel
Publikováno v:
Biological Psychiatry. 89:S143
Autor:
Mary S. Richardson, Jackie W. Kwong, Paul Winner, Lisa K. Mannix, D. Gayla Putnam, Stephen O'Quinn, Scott McNeal
Publikováno v:
Mayo Clinic Proceedings. 78:1214-1222
To evaluate the efficacy and tolerability of sumatriptan, 50-mg and 100-mg tablets, compared with placebo for treatment of migraine at the first sign of pain.Two identical multicenter randomized, double-blind, placebo-controlled, single-attack studie
Autor:
Donna L. Gutterman, Roger Cady, Stephen O'Quinn, Richard B. Lipton, Walter F. Stewart, Charles B. Hall
Publikováno v:
Headache: The Journal of Head and Face Pain. 40:792-797
Objective.—To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods.—A post hoc analysis was performed in a subgroup of patients from
Autor:
Stephen O'Quinn, Richard B. Lipton, Donna L. Gutterman, Roger Cady, Walter F. Stewart, Timothy Kuhn, Charles B. Hall
Publikováno v:
Headache: The Journal of Head and Face Pain. 40:783-791
Background.—Migraineurs experience a spectrum of headaches: migraine, migrainous, and episodic tension-type as defined by the International Headache Society (IHS). Objective.—To evaluate the effectiveness of sumatriptan, 50-mg tablets, in treatin
Publikováno v:
Headache: The Journal of Head and Face Pain. 40:103-110
Objective.–To evaluate clinical parameters that may affect the incidence of headache recurrence or the time to headache recurrence, or both, in migraineurs treated with naratriptan, 2.5-mg tablets. Background.–The incidence of headache recurrence
Publikováno v:
Cephalalgia. 19:668-675
Polypharmacy (the prescription of more than one therapy for a single patient) and subcutaneous (s.c.) sumatriptan tolerability were prospectively studied in 12,339 migraineurs, each followed for up to 1 year. Inclusion/exclusion criteria were minimal
Publikováno v:
Headache: The Journal of Head and Face Pain. 40:605-607